QT Imaging Holdings, Inc., a medical device company focused on radiation-free breast imaging, has received approval to uplist its common stock from the OTCQB Venture Market to the Nasdaq Capital Market. The company’s shares are expected to begin trading on Nasdaq under the ticker symbol “QTI” on Wednesday, January 28, 2026.
The move marks a significant milestone for the company, which was delisted less than a year ago. QT Imaging said it has now met all Nasdaq Capital Market listing requirements, including financial, corporate governance, and regulatory standards.
“We are very pleased to have received approval to reestablish our listing on the Nasdaq Capital Market,” said Dr. Raluca Dinu, Chief Executive Officer of QT Imaging. “This milestone represents relentless work to turn the company around, rebuild its business model, its balance sheet, and restore trust. Our team pushed through uncertainty with discipline and resilience, supported by stockholders who stayed with us.”
QT Imaging develops radiation-free imaging technology designed to improve breast health management. The company positions its platform as an alternative to traditional imaging methods, with a focus on patient safety, comfort, and earlier diagnostic insights.
“QT Imaging exists for a simple and deeply personal reason,” Dinu said. “Women deserve better options for breast imaging, earlier answers, and care that puts their safety and dignity first. Everything we have done has been in service of bringing this technology from the lab into the hands of clinicians and the women they serve.”
The company said returning to Nasdaq is expected to increase its market visibility, broaden its investor base, and support long-term value creation. QT Imaging believes the uplisting also aligns with its broader strategy to expand its global footprint and accelerate the adoption of its imaging technology.
“As a stronger company with a clear mission, we believe a Nasdaq listing supports sustainable growth,” Dinu added.
QT Imaging stated it remains committed to disciplined execution, operational excellence, and innovation as it enters this next phase. The company said investors can expect further updates as it advances its strategic and commercial objectives in the coming months.
